Filippo de Braud

Research interests

Publications

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Caring for patients with cancer in the COVID-19 era

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0874-8

• The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0894-7

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30321-1

• Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies

  International Journal of Cancer · 2020 · https://doi.org/10.1002/ijc.33013

• Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30690-4

• Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

  British Journal of Cancer · 2018 · 10.1038/s41416-018-0334-0

• CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.6212

• Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx176

• ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

  JNCI Journal of the National Cancer Institute · 2017 · https://doi.org/10.1093/jnci/djx089

• Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

  Cancer Discovery · 2017 · 10.1158/2159-8290.cd-16-1237

• Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

  Nature · 2017 · https://doi.org/10.1038/nature24673

• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30450-3

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30098-5

• Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30496-x

• Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

  Cancer Discovery · 2016 · https://doi.org/10.1158/2159-8290.cd-15-1335

• Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

  European Journal of Cancer · 2015 · https://doi.org/10.1016/j.ejca.2015.01.054

• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)60898-4

• Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1406037

• Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

  Nature Genetics · 2013 · https://doi.org/10.1038/ng.2813

• Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.6297

• Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

  Annals of Oncology · 2011 · https://doi.org/10.1093/annonc/mdq632

• Colon cancer

  Critical Reviews in Oncology/Hematology · 2010 · 10.1016/j.critrevonc.2010.01.010

• Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.20.8397

• XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.11.069

• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

  Annals of Oncology · 2002 · 10.1093/annonc/mdf013

• Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

  Journal of Clinical Oncology · 2000 · https://doi.org/10.1200/jco.2000.18.16.2938

Current projects

No projects listed.